BioInvent: Additional BT-001 Combination Data - Redeye
Redeye comments on the updated clinical data from the phase I study combining the oncolytic virus TB-001 with pembrolizumab that will be presented in a poster at ESMO. They support further development.
ANNONS
Redeye comments on the updated clinical data from the phase I study combining the oncolytic virus TB-001 with pembrolizumab that will be presented in a poster at ESMO. They support further development.
